Berg LLC

Bpgbio, Inc.

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

University of Miami

Rangaprasad Sarangarajan

Niven Rajin Narain

John Patrick McCook

Shen Luan

Shiv Srivastava

Sylvia Daunert

Vivek Kannoth Vishnudas

Joaquin J Jimenez

Viatcheslav R Akmaev

Sapna K Deo

Enxuan Jing

Stephane Gesta

Michael Andrew Kiebish

Nikunj Narendra Tanna

Thomas Mitchell Gray

Min Du

Tony Walshe

Vivek K Vishnudas

Albert Dobi

Emre Dikici

John Patrick Mccook

Leonardo Rodrigues

Anne R Diers

Paula Patricia Narain

Lixia Zhang

Jennifer Cullen

Jeremy Chaufty

Eric Milliman

Reinhard Roessler

Pirouz Mohammad Daftarian

Joaquin Juan Jimenez

Methods for identifying a modulator of angiogenesis and methods for modulating angiogenesis in a mammalian subject are described herein. In some embodiments, the methods include obtaining data sets from a model for angiogenesis and generating a causal relationship network model based on the obtained data. In some embodiments, the methods include identifying, from the causal relationship network model, a causal relationship unique in angiogenesis, where a gene, lipid, protein, metabolite, transcript, or SNP associated with the unique causal relationship is identified as a modulator of angiogenesis.

Interrogatory cell-based assays and uses thereof

Methods for diagnosing the presence of BCR in prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of BCR. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

Markers for the diagnosis of biochemical recurrence in prostate cancer

The invention provides methods and compositions for treatment of a subject with a glioma that has failed treatment with temozolomide (TMZ) comprising administration of a composition comprising a Coenzyme Q10 compound to the subject. The invention also provides a method of treating a cancer that exhibits increased Complex II activity in a subject comprising administration of a composition comprising a Coenzyme Q10 compound to the subject.

Methods of treatment of temozolomide-resistant glioma using coenzyme Q10

Described herein is a discovery Platform Technology for analyzing a drug-induced toxicity condition, such as cardiotoxicity via model building.

Interrogatory cell-based assays for identifying drug-induced toxicity markers

Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building.

The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.

Method of treating or preventing tumors of the central nervous system

The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject.

Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa

The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

Methods of treatment of cancer by continuous infusion of coenzyme Q10

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

Enolase 1 (ENO1) compositions and uses thereof

The invention provides methods for rapid and quantitative extraction and detection of coenzyme Q10 in a sample readily adaptable to high throughput screening methods. The invention further provides reagents and kits for practicing the methods of the invention.

Methods and kits for detection of coenzyme Q10

The present invention provides methods for treating Parkinson's Disease (PD), e.g., PD associated with a genetic mutation in a glucocerebrosidase (GBA) gene or a leucine rich repeat kinase 2 (LRRK2) gene. The methods comprise administering to the subject a modulator, e.g., an inhibitor, of p53-inducible gene 3 (PIG3).

Methods for treating Parkinson's disease

Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

Methods for the treatment of cancer using coenzyme Q10 combination therapies

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

Use of markers including filamin A in the diagnosis and treatment of prostate cancer

Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.

Growing community of inventors

Boylston, MA, United States of America

Rangaprasad Sarangarajan